Home » Stocks » EYES

Second Sight Medical Products, Inc. (EYES)

Stock Price: $2.48 USD 0.39 (18.66%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $2.32 -0.16 (-6.45%) Jan 26, 7:57 PM
Market Cap 57.57M
Revenue (ttm) 497,000
Net Income (ttm) -21.46M
Shares Out 23.12M
EPS (ttm) -1.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $2.48
Previous Close $2.09
Change ($) 0.39
Change (%) 18.66%
Day's Open 2.58
Day's Range 2.32 - 2.91
Day's Volume 20,546,205
52-Week Range 0.73 - 6.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artific...

Forbes - 6 months ago

Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the m...

Other stocks mentioned: APVO, BLNK, EFOI, SGBX
Forbes - 6 months ago

If you're wondering how markets are still surging in light of record-breaking coronavirus cases, our deep learning algorithms paired with Artificial Intelligence (“AI”) technology has you cove...

Other stocks mentioned: BHF, JAGX, RMBL, SLNO
Forbes - 6 months ago

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead o...

Other stocks mentioned: BKYI, COCP, EYPT, REPH
Zacks Investment Research - 7 months ago

Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the ne...

Zacks Investment Research - 8 months ago

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 10 months ago

Second Sight Medical Products' (EYES) CEO Will McGuire on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 4.08% and -40.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ah...

Zacks Investment Research - 10 months ago

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Second Sight Medical Products, Inc's (EYES) CEO Will McGuire on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and -49.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies a...

Zacks Investment Research - 1 year ago

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Second Sight Medical Products, Inc. (EYES) CEO Will McGuire on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and 183.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead ...

Zacks Investment Research - 1 year ago

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Second Sight Medical Products, Inc. (EYES) CEO Jonathan McGuire on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of -66.67% and -33.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahe...

Seeking Alpha - 1 year ago

Second Sight Medical Products, Inc. (EYES) CEO Will McGuire on Q4 2018 Results - Earnings Call Transcript

About EYES

Second Sight Medical Products, together with its subsidiaries, develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injur... [Read more...]

Industry
Medical Devices
IPO Date
Nov 19, 2014
CEO
Matthew J. Pfeffer CPA
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
EYES
Full Company Profile

Financial Performance

In 2019, EYES's revenue was $3.38 million, a decrease of -51.00% compared to the previous year's $6.90 million. Losses were -$33.59 million, -4.28% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for EYES is 2.50, which is an increase of 0.81% from the latest price.

Price Target
$2.50
(0.81% upside)